Treatment Naïve and Treatment Experienced

Sofosbuvir + (Ledipasvir or GS-9669) +/- Ribavirin in GT-1 ELECTRON Trial (Arms 12-17 & 22)

Source: Gane EJ, et al. Gastroenterogy. 2014:146:736-43.




Sofosbuvir + (Ledipasvir or GS-9669) +/- Ribavirin in GT1 ELECTRON Trial (Arms 12-17 & 22): Features

ELECTRON Trial (Arms 12-17 & 22)

- Design: Open-label, phase 2, using sofosbuvir plus [ledipasvir or GS-9669]
 with or without ribavirin in treatment-naïve and treatment-experienced GT1
- Setting: two hepatitis treatment centers in New Zealand
- Entry Criteria
 - Chronic HCV genotype 1
 - HCV RNA >50,000 IU/mL
 - Age >18 years
- Patient Characteristics (range in different treatment arms)
 - n = 113 patients enrolled
 - Three of seven groups were treatment naïve
 - Four of seven groups were treatment experienced with prior null response
 - Two groups of seven groups were treatment experienced and cirrhotic
 - Three treatment arms used fixed dose ledipasvir-sofosbuvir
- Primary End-Point: SVR12



Sofosbuvir + (Ledipasvir or GS-9669) +/- Ribavirin in GT1 ELECTRON Trial Arms (12-17 & 22): Design



Abbreviations: LDV= ledipasvir; SOF = sofosbuvir; RBV = ribavirin

Drug Dosing


Sofosbuvir: 400 mg once daily; Ledipasvir: 90 mg once daily; GS-9669 = 500 mg once daily Ledipasvir-sofosbuvir (90/400 mg): fixed dose combination one pill once daily Ribavirin (weight-based and divided bid): 1000 mg/day if < 75kg or 1200 mg/day if ≥ 75kg

Source: Gane EJ, et al. Gastroenterogy. 2014:146:736-43.



Sofosbuvir + (Ledipasvir or GS-9669) +/- Ribavirin in GT1 ELECTRON Trial (Arms 12-17 & 22): Results

ELECTRON TRIAL, SVR 12 by Treatment Regimen



^{*}All regimens 12 weeks except treatment-naïve LDV-SOF + Ribavirin= 6 week regimen



Sofosbuvir + (Ledipasvir or GS-9669) +/- Ribavirin in GT1 ELECTRON Trial (Arms 12-17 & 22): Conclusion

Conclusions: "The combination of sofosbuvir and a second direct-acting antiviral agent is highly effective in treatment-naïve patients with HCV genotype 1 infection and in patients that did not respond to previous treatment."

